Japan Tissue Engineering Co., Ltd. (7774.T)
- Previous Close
649.00 - Open
647.00 - Bid 651.00 x --
- Ask 662.00 x --
- Day's Range
634.00 - 667.00 - 52 Week Range
472.00 - 811.00 - Volume
38,600 - Avg. Volume
73,133 - Market Cap (intraday)
26.803B - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
-- - EPS (TTM)
-3.89 - Earnings Date Apr 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. is a subsidiary of Teijin Limited.
www.jpte.co.jpRelated News
Performance Overview: 7774.T
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 7774.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 7774.T
Valuation Measures
Market Cap
26.80B
Enterprise Value
22.67B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.29
Price/Book (mrq)
4.56
Enterprise Value/Revenue
9.55
Enterprise Value/EBITDA
-145.94
Financial Highlights
Profitability and Income Statement
Profit Margin
-6.61%
Return on Assets (ttm)
-1.41%
Return on Equity (ttm)
-2.63%
Revenue (ttm)
2.37B
Net Income Avi to Common (ttm)
-157M
Diluted EPS (ttm)
-3.89
Balance Sheet and Cash Flow
Total Cash (mrq)
4.06B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Company Insights: 7774.T
7774.T does not have Company Insights